Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001225208-12-019632)

Filing Details

Accession Number:: 0001225208-12-019632
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2012-09-14 13:42:44
Reporting Period:: 2012-09-14

Filing Date:: 2012-09-14
Accepted Time:: 2012-09-14 13:42:44
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
810509	Navidea Biopharmaceuticals Inc.	NAVB	In Vitro & In Vivo Diagnostic Substances (2835)	311080091

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1528192	H. Thomas Tulip	425 Metro Place North Suite 450 Dublin OH 43017		No	No	No	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-09-14	15,000	$2.70	27,500	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	940	Indirect	By 401(k)

Footnotes

Price represents a weighted average of the purchase price. Shares were purchased at prices ranging from $2.66 to $2.72. Upon the request by the SEC staff, the Issuer, or a security holder of the Issuer, the reporting person will provide the full information about the number of shares purchased at each separate price.
Total includes shares acquired under the Neoprobe Corporation 401(k) Plan.